The stock of Cyclacel Pharmaceuticals Inc (CYCC) has gone down by -44.14% for the week, with a -52.93% drop in the past month and a -32.86% drop in the past quarter. The volatility ratio for the week is 30.27%, and the volatility levels for the past 30 days are 15.24% for CYCC. The simple moving average for the past 20 days is -44.30% for CYCC’s stock, with a -49.55% simple moving average for the past 200 days.
Is It Worth Investing in Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC) Right Now?
The 36-month beta value for CYCC is also noteworthy at 0.93. There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The average price estimated by analysts for CYCC is $15.00, which is $14.7 above than the current price. The public float for CYCC is 10.87M, and at present, short sellers hold a 4.71% of that float. The average trading volume of CYCC on November 20, 2023 was 133.84K shares.
CYCC) stock’s latest price update
Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC)’s stock price has gone decline by -13.90 in comparison to its previous close of 0.35, however, the company has experienced a -44.14% decrease in its stock price over the last five trading days. GlobeNewsWire reported 2023-11-07 that BERKELEY HEIGHTS, N.J., Nov. 07, 2023 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce third quarter 2023 financial results on Monday, November 13, 2023. The Company will host a conference call and live webcast at 4:30 p.m. Eastern Time on the same day.
Analysts’ Opinion of CYCC
Many brokerage firms have already submitted their reports for CYCC stocks, with Oppenheimer repeating the rating for CYCC by listing it as a “Outperform.” The predicted price for CYCC in the upcoming period, according to Oppenheimer is $17 based on the research report published on July 18, 2022 of the previous year 2022.
CYCC Trading at -33.42% from the 50-Day Moving Average
After a stumble in the market that brought CYCC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -74.17% of loss for the given period.
Volatility was left at 15.24%, however, over the last 30 days, the volatility rate increased by 30.27%, as shares sank -52.41% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -1.88% lower at present.
During the last 5 trading sessions, CYCC fell by -44.14%, which changed the moving average for the period of 200-days by -72.28% in comparison to the 20-day moving average, which settled at $0.5259. In addition, Cyclacel Pharmaceuticals Inc saw -54.69% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for CYCC
The total capital return value is set at -96.36, while invested capital returns managed to touch -73.86. Equity return is now at value -160.25, with -114.00 for asset returns.
Based on Cyclacel Pharmaceuticals Inc (CYCC), the company’s capital structure generated 0.53 points at debt to equity in total, while total debt to capital is 0.53. Total debt to assets is 0.39, with long-term debt to equity ratio resting at 0.68. Finally, the long-term debt to capital ratio is 0.53.
When we switch over and look at the enterprise to sales, we see a ratio of -37.07, with the company’s debt to enterprise value settled at -0.02. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.30.
Conclusion
In summary, Cyclacel Pharmaceuticals Inc (CYCC) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
